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7 Abstract
8 Aberrant activation of the Wnt signaling pathway is an
9 important step in the initiation and progression of tumor
10 development in diverse cancers. The central effector of canon-
11 ical Wnt signaling, b-catenin (CTNNB1), is a multifunctional
12 protein, and has been extensively studied with respect to its
13 roles in cell–cell adhesion and in regulation of Wnt-driven
14 transcription. Here, a novel mass spectrometry–based proteo-
15 mics technique in colorectal cancer cells expressing stabilized
16 b-catenin, was used to identify a protein–protein interaction
17 between b-catenin and DNA methyltransferase I (Dnmt1) pro-
18 tein, the primary regulator of DNA methylation patterns in
19 mammalian cells. Dnmt1 and b-catenin strongly colocalized in
20 the nuclei of colorectal cancer cells, and the interaction is
21 mediated by the central domain of the Dnmt1 protein. Dnmt1
22 protein abundance is dependent upon the levels of b-catenin,
24and is increased in cells expressing stabilized mutant b-catenin.
25Conversely, the Dnmt1 regulates the levels of nuclear b-catenin
26and b-catenin/TCF–driven transcription. In addition, lysine-
27speciﬁc demethylase 1 (LSD1/KDM1A), a regulator of DNMT1
28stability, was identiﬁed as a component of the Dnmt1–b-cate-
29nin protein complex and perturbation of the Dnmt1–b-catenin
30interaction altered DNA methylation. In summary, a functional
31protein–protein interaction was identiﬁed between two criti-
32cally important oncoproteins, in turn revealing a link between
33Wnt signaling and downstream nuclear functions mediated by
34Dnmt1.
35Implications: Two critical oncoproteins, Dnmt1 and b-catenin,
36mutually regulate one each other's levels and activities in colo-
37rectal cancer cells. Mol Cancer Res; 1–13. 2015 AACR.
38
39 Introduction
40 Cancer cells typically exhibit complex, multilayered perturba-
41 tions of signaling pathways and regulatory mechanisms (1).
42 Dysregulation of the Wnt signaling pathway is a major factor in
43 the initiation and progression of colorectal cancer. Canonical or
44 b-catenin-dependent Wnt signaling is the best-deﬁned branch of
45 Wnt signaling, and is activated by binding of a Wnt ligand with
46 speciﬁc cell surface receptor complexes. The subsequent signaling
47 cascade leads to accumulation and nuclear translocation of
48 b-catenin, the central effecter of canonical Wnt signaling. Activat-
49 ing mutations of b-catenin, which stabilize the protein, or loss of
50 function of tumor suppressors such as adenomatous polyposis
51 coli (APC), are causal events in the initiation of colorectal cancer
53(2, 3). b-Catenin is one of the best studied oncoproteins and
54diverse b-catenin protein–protein interactions have been identi-
55ﬁed. Recent studies, for example, have revealed the association of
56b-catenin with chromatin and epigenetic modifying complexes
57(4, 5), and it is clear that our knowledge of b-catenin protein
58function is quite incomplete.
59In this study, we identify a protein–protein interaction between
60b-catenin and Dnmt1, the primary maintenance DNA methyl-
61transferase in mammalian cells. Dnmt1 (Dnmt1 refers to the
62protein product of the DNMT1 gene) expression is altered in
63many different tumors (6–10), although somatic mutations of
64DNMT1 are relatively rare events in human cancers. Although best
65known for its role inDNAmethylation, other functions have been
66deﬁned for Dnmt1 protein, including the formation of transcrip-
67tional repressor complexes withHDACandDMAP1proteins (11)
68and with the LSD1 histone demethylase (12). In addition, many
69protein–protein interactions between Dnmt1 and transcription
70factors have been identiﬁed, principally mediated via the N-
71terminal regulatory region of the protein (13). DNMT1 itself is
72subject to multiple layers of regulation, including transcriptional
73(14) and posttranslational regulation through control of Dnmt1
74protein stability (13, 15, 16). How these different mechanisms
75contribute to regulation of Dnmt1 (and DNA methyltransferase
76activities in general) in cancer cells is only partially understood. In
77addition, in many cancer cells aberrant expression of DNA
78methyltransferases occurs alongside dysregulated signal transduc-
79tion pathways, but the extent to which signaling pathways reg-
80ulate Dnmt1 and associated functions remains to be determined.
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83 Here, we use mass spectrometry, coimmunoprecipitation
84 (co-IP), and confocal microscopy to identify and characterize
85 the Dnmt1–b-catenin interactionQ4 . We show that the interaction
86 is mediated by the central portion of the Dnmt1 protein and
87 that Dnmt1 and b-catenin protein levels are mutually depen-
88 dent. We show that Dnmt1 protein levels are responsive to
89 exogenous Wnt activation that the response is not mediated via
90 transcriptional mechanisms. Finally, to investigate the func-
91 tional consequences of the Dnmt1–b-catenin interaction, we
92 show that the interaction with Dnmt1 protein regulates both
93 the level of b-catenin and b-catenin/TCF–driven transcriptional
94 activity, and that CpG methylation of an imprinted locus is
95 signiﬁcantly reduced in cells lacking b-catenin. In summary, our
96 study identiﬁes a novel mechanism by which the levels of these
97 two important oncoproteins are regulated in cancer cells and
98 points to a regulatory link between Wnt signaling and epige-
99 netic functions of Dnmt1.
100 Materials and Methods
101 Cell culture
102 Colorectal cancer cell lines RKO and HCT116 were main-
103 tained in McCoy-5A media (Life Technologies, 16600-108)
104 containing 10% FBS (Life Technologies, 10438-026) and 1%
105 streptomycin–penicillin (Life Technologies, 15140-148) at
106 37C in CO2 incubator (5% CO2, 100% H2O). The human
107 embryonic kidney cell line HEK293T was maintained in DMEM
108 media (Life Technologies, 11965-092) containing 10% FBS and
109 1% streptomycin–penicillin under the same conditions. For
110 Wnt activation, media were removed and the cells were washed
111 twice with serum-free McCoy5A media, and 1 mL serum-free
112 McCoy5A media, added in each well of 6-well cell culture plate
113 with puriﬁed Wnt3a protein (R&D Systems, Inc. 5036-WNP-
114 010/CF) at the required ﬁnal concentration of 30 ng/mL (17),
115 and the cells were cultured for an additional 0.5, 1, 2, 3, 6, 12,
116 or 24 hours before harvesting. Cells were harvested by scraping
117 the cells off plates and then washed with cold PBS twice for
118 immediate use or storage (–80C). Knockout cell lines were
119 provided by the respective laboratories in which they were
120 generated and cultured under the same conditions as the parent
121 cell lines (18, 19).
122 Protein extraction and quantiﬁcation
123 Harvested cells were lysed in buffer (25 mmol/L Tris-HCl,
124 pH7.4, 1 mmol/L EDTA, 150mmol/L NaCl, 1% NP-40, 50%
125 glycerol, Protease inhibitor cocktail) by homogenization and
126 incubated on ice for 30 minutes followed by centrifugation at
127 13,000 rpm for 30 minutes. Benzonase nuclease (Sigma E1014)
128 was added to the lysis buffer as required and the supernatant
129 (soluble fraction) kept for further analysis. Proteins were quan-
130 tiﬁed by Bio-Rad protein assay dye (Bio-Rad 500-0006) at 595
131 nm.
132 RNA extraction and RT-PCR
133 Total RNAwas extracted fromWnt3a stimulatedHEK293T time
134 course cells using the RNeasy Mini Kit (Qiagen, 74104) and 1 mg
135 RNA was used in one step RT-PCRs using SuperScript One-Step
136 RT-PCR with Platinum Taq (Life Technologies 10928-034)
137 on DNMT1 with forward primer 50-GTGGGGGACTGTGTCTC-
138 TGT-30and reverse primer 50-TGCTGCCTTTGATGTAGTCG-30,
140CTNNB1 with forward primer 50-AAGCCTCTCGGTCTGTGG-30
141and reverse primer 50-TGATGGTTCAGCCAAACGCT-30, and
142GAPDH with forward primer 50-CCGTCTAGAAAAACCTGCC
143-30 and reverse primer 50-GCCAAATTCGTTGTCATACC-30 as load-
144ing control.One-step RT-PCR conditionswere set according to the
145manufactory's protocol (Life Technologies 10928-034) with
146annealing temperature at 55C. The ampliﬁed DNA products
147were then electrophoreed on 1.5% agarose gel containing SYBR
148Safe DNA gel stain (Life Technologies, S33102).
149Flow-cytometry analysis
150HEK293T cells at different time points (0, 0.5, 1, 2, 3, 6, 12, and
15124 hours) after stimulation were collected, washed twice with ice-
152cold PBS buffer (137 mmol/L NaCl, 2.7 mmol/L KCl, 8 mmol/L
153Na2HPO4, 1.46 mmol/L KH2PO4), resuspended in 50 mL PBS
154buffer and ﬁxed with 450 mL 100%Methanol in –20C for at least
15520 minutes. The cells were then treated with RNase (Life Tech-
156nologies, 12091, Carlsbad, CA) in for 30 minutes before stained
157with 100 mg/mL propidium iodide and subsequently subjected to
158ﬂow-cytometry analyzer (Beckman Coulter Epics XL ﬂow cyt-
159ometer). A minimum of 10,000 cells within the gated region
160were analyzed and data were captured and presented by Expo32
161ADC Cytometry List Mode Data Acquisition & Analysis Software.
162SDSPAGE and immunoblotting
163Equal amounts (20 mg) of proteins from different samples
164were loaded on precast 4% and 12% Bis-Tris gel (Life Technol-
165ogies NP-0335). Following electrophoresis, gels were either
166stained with Coomassie Brilliant Blue (Pierce 20278) or trans-
167ferred to nitrocellulose membrane (Whatman 10402594). West-
168ern blotting was used to detect the protein with super signal
169ELISA Pico chemiluminescent substrate. Primary antibodies
170anti–b-catenin (Cell Signaling Technology 9581), anti–b-cate-
171nin (active; Cell Signaling Technology 8814), anti-Dnmt1 (Cell
172Signaling Technology 5119), and anti–a-tubulin (Cell Signaling
173Technology, Inc.) as loading control were applied at 1:1,000 and
174secondary antibodies horseradish peroxidase (HRP)–conjugated
175anti-mouse (Promega W4011) and HRP-conjugated anti-rabbit
176(Cell Signaling Technology 7074) were added at 1:20,000.
177Chemiluminescence detection using SuperSignal ELISA Pico
178Chemiluminescent Substrate (Thermo Scientiﬁc PI-37070) was
179applied to all westerns. Bands were quantiﬁed by ImageJ (http://
180rsbweb.nih.gov/ij/; refs. 18, 19) and the mean values and SDs
181computed for three replicates.
182Proteomic analysis
183Standard in-gel tryptic digestion was performed according to
184the publishedmethod (20). The combined elution fractions were
185lyophilized in a SpeedVac Concentrator (Thermo Electron Cor-
186poration), resuspended in 100 mL of 0.1% formic acid and further
187cleaned up by reverse phase chromatography using C18 column
188(Harvard). The ﬁnal volume was reduced to 10 mL by vacuum
189centrifugation and addition of 0.1% formic acid. Tryptic peptides
190were separated by online reverse phase nanoscale capillary liquid
191chromatography (nano-LC, Dionex Ultimate 3000 series HPLC
192system) coupled to electoral spray injection (ESI) tandem mass
193spectrometer (MS/MS) with octopole collision cell (Thermo-
194Finnegan LTQ Orbitrap). Loaded peptides were eluted on
195nano-LC with 90 minutes gradients ranging from 6% to 73%
196acetonitrile in 0.5% formic acid with a ﬂow rate of 300 nL/min.
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199 Data-dependent acquisition was performed on the LTQ-Orbitrap
200 using Xcalibur software (version2.0.6; Thermo Fisher Scientiﬁc)
201 in the positive ion mode with a resolution of 60,000 at m/z
202 range of 325.0 to 1,800.0, and using 35% normalized collision
203 energy, up to ﬁve most intensive multiple charged ions were
204 sequentially isolated, fragmented and further analyzed.
205 Mass spectrometry data processing
206 Raw LC-MS/MS data were processed using Mascot version
207 2.2.0 (Matrix Science). The sequence database was searched
208 with a fragment ion mass tolerance of 0.8 Da and a parent ion
209 tolerance of 15 PPM. The raw data were searched against the
210 human International Protein Index database (released in 2009
211 and containing 74,017 protein sequences) with ﬁxed modi-
212 ﬁcation carbamidomethyl (C) and variable modiﬁcation oxi-
213 dation (M). The ﬁve fractions for each sample were combined
214 as a single search in Mascot. Peptides were ﬁltered at a signif-
215 icance threshold of P < 0.05 (Mascot). Scaffold (Proteome
216 Software Inc.; version 3.00.04) was used to analyze LC-MS/
217 MS–based peptide and protein identiﬁcations (21). Peptide
218 identiﬁcations were accepted if they could be established at
219 greater than 95.0% probability as speciﬁed by the Peptide
220 Prophet algorithm (22). Protein identiﬁcations were accepted
221 if they could be established at greater than 99.0% probability
222 and contained at least two identiﬁed peptides (22).
223 Immunoﬂuorescence
224 Cells were grown to 50% conﬂuence on cover slip slides (12-
225 545-80, Fisherbrand Cover Glasses) overnight and ﬁxed ﬁrst with
226 4% formaldehyde in PBS (phosphate Buffered Saline) for 15
227 minutes at room temperature. Fixed cells were blocked with
228 blocking buffer composed of 1 PBS with 5% goat serum (Cell
229 Signaling Technology 5425) and 0.3% Triton X-100 for 60 min-
230 utes at room temperature. Cells were then probed with an anti-
231 FLAG (Sigma F1804) sera at dilution of 1:200 and b-catenin
232 (D10A8) XP Rabbit antibody (Cell Signaling Technology
233 8480) at dilution of 1:100 for 2 hours at room temperature,
234 washed with PBS buffer three times of 5 minutes each, then
235 incubated with secondary Alexa Fluor 594 Goat Anti-Mouse IgG,
236 highly cross-adsorbed antibody (Life Technologies A31624) and
237 Alexa Fluor 488 Goat Anti-Rabbit IgG (HþL), highly cross-
238 adsorbed antibody (Life Technologies A11034) at a dilution of
239 1:1,000 for 30 minutes at room temperature in dark. Nuclei were
240 stained with DAPI (Cell Signaling Technology 8961). Next, the
241 Slides were rinsed with PBS and Prolong Gold Anti-Fade Reagent
242 (Cell Signaling Technology 9071) was applied. Slides were then
243 analyzed and imageswere taken on Leica TCS SP2AOBS ﬁlter-free
244 UV/spectral confocal laser scanner on an inverted DM IRE2
245 microscope.
246 RNAi
247 HCT116 and RKO cells were transfected with targeted siRNAs
248 against DNMT1 and CTNNB1 using Lipofectamine 2000 trans-
249 fection reagent (Life Technologies, cat no. 11668) and the
250 cells were then incubated at 37oC in CO2 incubator and har-
251 vested 48 hours after transfection. Three gene unique 27mer
252 siRNAs for each target were synthesized by Origene. The three
253 target sequences of DNMT1are ACCAAAUUACGUAAAGAA-
254 GAAUUAT (SR301244A), AGCACAGAAGUCAACCCAAAGAU-
255 CT (SR301244B) and UGAGUGGAAAUUAAGACUUUAUGTA
257(SR301244C). The three target sequences of CTNNB1 are
258GGAUCACAAGAUGGAAUUUAUCAAA (SR301063A), CGCA-
259UGGAAGAAAUAGUUGAAGGTT (SR301063B), and AGAAUU-
260GAGUAAUGGUGUAGAACAC (SR301063C). Control siRNA
261(SR30004) is designed and provided by Origene.
262LEF/TCF reporter assays
263Targeted cells (HCT116, RKO, DNMT1KO-HCT116, and
264CTNNB1KO-HCT116) were seeded onto multiwall plates one
265day before transfection and grown to 70% and 90% conﬂuence.
266Vectors of LEF/TCF reporter, negative control, and positive
267control were then individually premixed with transfection
268reagent Lipofectamine2000 (Life Technologies 11668) and
269Opti-MEM serum-free culture medium and incubated at room
270temperature for 20 minutes. For cotransfection with siRNA,
271three target sequences of either DNMT1 or CTNNB1 (see
272previous description in RNAi) were added into the premix and
273incubated at room temperature for 20 minutes before use.
274Luciferase assay was performed using Dual-Luciferase reporter
275assay system (Promega 1910) 48 hours after transfection. The
276cells were lysed in plate using passive lysis buffer (Promega
2771941) for 15 minutes at room temperature with gentle shaking.
278Cell lysates were then transferred into a 96-well plate and
279development substrates were added according to the instruc-
280tions (Promega 1910, Madison, WI). Fireﬂy luciferase and
281Renilla luciferase activity were measure by microplate reader
282premium Quad4 Monochromators (Tecan Group Inc. Inﬁnite
283M1000 pro). The promoter activity values were expressed as
284arbitrary units using a Renilla reporter for internal normaliza-
285tion according to the manufactory's protocol (Promega 1910).
286For experiments using TOPFlash/FOPFlash plasmids used were
287M50 and M51 Super 8x TopFLASH (Addgene; ref. 23). Experi-
288ments were done in triplicates for all biologic cell cultures/
289transfections and luminescent measurements. Mean (bar
290height) of relative luciferase units for each sample plus SD
291(error bar) were then calculated and plotted.
292Quantiﬁcation of protein half-life
293HCT116, DNMT1KO-HCT116, and CTNNB1KO-HCT116 were
294grown in separate 6-well plates to log phase. Cycloheximide (Cell
295Signaling Technology 2112) was added to a ﬁnal concentration
296of 50 mg/mL to terminate protein synthesis. After cycloheximide
297treatment, equal numbers of cells were collected at 0, 3, and 6
298hours, and cell lysates were prepared as described. The lysates
299were analyzed by SDSPAGE and Western blotting. Bands corre-
300sponding to each protein were detected by using chemilumines-
301cence and the intensity of bands was quantiﬁed using ImageJ.
302Half-life (T1/2) was calculated as previously described (24).
303Methylation analysis of H19 CpG islands
304Genomic DNA was extracted with the QIAamp DNA Mini Kit
305(Qiagen 51804). Bisulﬁte treatment of the genomic DNA samples
306was carried out with the Qiagen EpiTect Kit (Qiagen 59104)
307according to the manufacturer's instructions, followed by PCR
308ampliﬁcation with speciﬁc primers for H19 promoter region
309(forward: 50-GGTCCCA/ideoxyU/ATGTAAGATTTTGGTGGAA-
310TAT-30; reverse: 50-GGCATAG/ideoxyU/ACAAACTCACACATCA-
311CAACC-30). The PCR products were gel-puriﬁed, inserted into
312USER cloning vector zw102 (courtesy of Wang laboratory), and
313sequenced with T3 universal primer.
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316 Results
317 A Dnmt1–b-catenin protein–protein interaction
318 We previously performed a large-scale proteomics study to
319 map the Wnt-responsive proteome (17). Proteins were identi-
320 ﬁed whose expression levels responded to exogenous Wnt3A
321 stimulation and we observed that Dnmt1 protein levels exhib-
322 ited a robust response to Wnt activation in HEK293T cells and in
323 the colorectal cancer cell-lines, RKO, and HCT116. In this study,
324 we used a novel afﬁnity puriﬁcation mass spectrometry (AP-MS)
325 technique previously applied by us to identify Dnmt1 protein–
326 protein interactions (15, 25). We introduced a 3xFLAG tag into
327 the DNMT1 locus in HCT116 cells (DNMT1KI-HCT116), expres-
328 sing a stabilized mutant b-catenin (i.e., with constitutive acti-
329 vation of Wnt signaling). The DNMT1KI-HCT116 cells were then
330 used in AP-MS experiments as previously described (25). We
331 ﬁltered the dataset to remove contaminants and nonspeciﬁc
332 binding proteins (26, 27, and then analyzed the identiﬁed
333 peptides and proteins (Supplementary Table S1). Peptides cor-
334 responding to b-catenin (2 distinct peptides) were identiﬁed
335 suggesting that Dnmt1 protein and b-catenin interact in
336 HCT116 cells.
337 To validate the association between b-catenin and Dnmt1
338 proteins, co-IP experiments were performed. First, anti-FLAG
339 immunoprecipitates fromDNMT1KI-HCT116 cells were analyzed
340 as shown in Fig. 1A. To assess whether the b-catenin–Dnmt1
341 interaction is chromatin-dependent, we performed the co-IP
342 experiments with and without the Benzonase nuclease (Supple-
343 mentary Fig. S2). No differences were observed in the Dnmt1
344 signal indicating a soluble b-catenin–Dnmt1 protein complex.
345 Western blots were also analyzed with anti-HAUSP/USP7 anti-
346 bodies as a positive control, because USP7 has been shown
347 previously to be associated with Dnmt1 protein complexes
348 (15, 28). A co-IP experiment using native anti-Dnmt1 antibodies
349 (instead of anti-FLAG) in parent HCT116 cells was also per-
350 formed, showing the same result (Supplementary Fig. S3) as the
351 anti-FLAG experiments. We next performed the reciprocal co-IP
352 experiment from DNMT1KI-HCT116 cells using native anti–
353 b-catenin antibodies and observed Dnmt1 proteins in these
354 samples (Fig. 1B), conﬁrming the association of b-catenin and
355 Dnmt1.
356 We previously performed AP-MS experiments on RKO cells
357 with FLAG-tagged DNMT1 (DNMT1KI-RKO; refs. 15, 25), but did
358 not identify b-catenin peptides in these experiments. We rea-
359 soned, however, that because endogenous b-catenin levels are
360 signiﬁcantly lower in RKO cells than in HCT116 cells, exogenous
361 activation of Wnt signaling in RKO cells might allow detection of
362 the b-catenin–Dnmt1 interaction in RKO cells. We therefore
363 treated DNMT1KI-RKO cells with Wnt3a before Western and
364 co-IP analysis as shown in Fig. 1C and D. Wnt3a treatment of
365 DNMT1KI-RKO cells increases b-catenin levels and b-catenin is
366 detected in anti-FLAG immunoprecipitates from DNMT1KI-RKO
367 cells. We also analyzed nuclear and cytosolic subcellular fractions
368 from DNMT1KI-HCT116 cells. Dnmt1 protein is strongly local-
369 ized to the nucleus of DNMT1KI-HCT116 cells (Fig. 1E) and anti-
370 FLAG IP from nuclear fractions identiﬁes b-catenin (Fig. 1F).
371 To map which regions of Dnmt1 protein are necessary for the
372 interaction with b-catenin, Myc-tagged deletion constructs of
373 Dnmt1 protein were constructed as shown in Fig. 1G. These were
374 expressed in HEK293 cells and immunoprecipitated for Western
375 analysis with anti–b-catenin antibodies. As shown in Fig. 1G,
377b-catenin is only detected in association with full-length Dnmt1
378protein or with the central region of the protein encompassing the
379zinc ﬁnger and two BAH (Bromo-adjacent homology) domains.
380Thus, neither the N-terminal region nor the C-terminal DNA
381methylase catalytic domains are necessary for the interaction of
382Dnmt1 protein with b-catenin.
383We next studied the subcellular localization of b-catenin–
384Dnmt1 association using confocal microscopy and immuno-
385ﬂuorescence to visualize the proteins in vivo (Fig. 2).
386DNMT1KI-HCT116 cells were either untreated (Fig. 2A) or
387treated withWnt3a (Fig. 2B), and analyzed using anti–b-catenin
388and anti-FLAG antibodies. As is clearly shown,b-catenin signal is
389detected in both the cytosolic and nuclear compartments,
390whereas Dnmt1 signal is conﬁned to the nucleus. The merged
391b-catenin and Dnmt1 signal shows strong colocalization of the
392two proteins in the nucleus, and this is most evident in cells
393treated with Wnt3a (Fig. 2B, panel iv).
394In summary, mass spectrometry, co-IP, and immunoﬂuores-
395cence results indicate that b-catenin and Dnmt1 proteins are co-
396complexed in the nucleus, that this interaction increases in
397response to Wnt3a, and that the interaction occurs in multiple
398different cell lines.
399Levels of Dnmt1 and b-catenin proteins are mutually
400dependent
401We next determined how the association between Dnmt1
402protein and b-catenin affects the levels of these two proteins.
403Two previously generated knockout cell lines, DNMT1/
404(DNMT1KO-HCT116; ref. 29), CTNNB1/ (CTNNB1KO-
405HCT116; ref. 30), and were compared with parent HCT116
406cells. Fig. 3A shows Western and RT-PCR analysis of parent
407HCT116 and CTNNB1KO-HCT116 cells. The levels of Dnmt1
408protein are substantially reduced in the CTNNB1KO-HCT116
409cells as compared with HCT116 parent cells. Notably, however,
410RT-PCR analysis reveals no difference between DNMT1 tran-
411script levels in CTNNB1KO-HCT116 and HCT116 cell lines,
412indicating that the lack of b-catenin does not affect DNMT1
413transcript levels. We also immunoblotted these samples
414using anti–g-catenin (plakoglobin) antibodies, and showed
415that the levels of plakoglobin are elevated in CTNNB1/ cells,
416consistent with the previously described observations that
417plakoglobin can independently promote Wnt/TCF signaling
418in b-catenin–deﬁcient cells (31). Figure 3B shows similar anal-
419ysis in DNMT1/ (DNMT1KO-HCT116) cells. b-catenin levels
420are substantially reduced in DNMT1KO-HCT116 as compared
421with HCT116 cells, although no difference in CTNNB1 tran-
422script levels is apparent. We re-introduced b-catenin into
423CTNNB1KO-HCT116 by transient transfection of a full-length
424b-catenin expression construct (Fig. 3C). As shown clearly in
425the Western analysis of these cells, re-expression of b-catenin
426rescues Dnmt1 protein expression in the CTNNB1/cells,
427indicating the dependence of Dnmt1 protein levels on b-cate-
428nin, although in the reciprocal experiment (Fig. 3D) in which
429Dnmt1 was expressed in DNMT1KO-HCT116 cells, signiﬁcant
430restoration of b-catenin protein levels was not observed.
431To investigate how Dnmt1 and b-catenin affect one another's
432stability, we measured protein half lives in the presence or
433absence of each protein. CTNNB1KO-HCT116 and DNMT1KO-
434HCT116 cells were treated with cycloheximide to block transla-
435tion and then the protein degradation proﬁles observed. As
436shown in Fig. 3E, we found that Dnmt1 has a signiﬁcantly shorter
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Figure 1.
Dnmt1 protein interacts with b-catenin in colorectal cancer cells. A, DNMT1 (FLAG) immunoprecipitates b-catenin in HCT116 cells. Total protein lysate from HCT116
with Benzonase untreated (–) or treated (þ) was used in the immunoprecipitation and elution fractions were loaded on gel and blotted. B, b-catenin
immunoprecipitates DNMT1 in HCT116 cells. C, b-catenin is induced by Wnt3a stimulation in both RKO and DNMT1KI-RKO cells. D, Dnmt1 (anti-FLAG)
immunoprecipitates b-catenin in DNMT1KI-RKO cells. E, subcellular fractionation and protein expression levels inDNMT1KI-HCT116 cells. F, Dnmt1 (anti-FLAG)
immunoprecipitates b-catenin in nuclear fraction of DNMT1KI-HCT116 cells. Twenty micrograms of proteins from each fraction was loaded on SDSPAGE followed by
Western blot analyses with anti-Dnmt1, anti-FLAG, anti–b-catenin, anti-HAUSP, anti–a-tubulin, and anti-GAPDH. (Continued on the following page.)
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439 half-life than b-catenin, and that in CTNNB1KO-HCT116 cells the
440 half-life is reduced by approximately 30%. b-Catenin has a longer
441 half-life that is reduced in the absence of Dnmt1. In
442 DNMT1KO-HCT116 cells, b-catenin half-life is reduced by approx-
443 imately 40% as compared with parent HCT116 cells.
444 DNMT1KO-HCT116 and CTNNB1KO-HCT116 cells were also
445 treated withMG-132 proteasome inhibitor and levels of b-catenin
446 and Dnmt1 analyzed by Western blot analysis (Supplementary
447 Fig. S6). In DNMT1KO-HCT116 cells, levels of b-catenin are
448 markedly increased by the addition of MG-132 whereas in
449 CTNNB1KO-HCT116 cells, levels of Dnmt1 increase in response
450 to MG-132, suggesting that the destabilization of Dnmt1 and
451 b-catenin is mediated via the proteasome and can be inhibited
452 through inhibition of proteasomal activity.
454To further study the interdependence of b-catenin and Dnmt1
455protein levels, we performed siRNA-mediated knockdown of
456DNMT1 or CTNNB1 in HCT116 and RKO cells. Knockdown of
457CTNNB1 in HCT116 (Fig. 4A) and in RKO cells (Fig. 4B) shows
458decreased levels of Dnmt1 protein in both cell lines. The effect is
459more marked in RKO cells than in HCT116 cells, and we noted
460that in HCT116 cells, siRNA-mediated CTNNB1 knockdown
461only partially reduced the levels of CTNNB1 (Fig. 4A), possibly
462due to the substantially higher levels of endogenous b-catenin in
463HCT116 cells. Similarly, knockdown of DNMT1 in HCT116
464(Fig. 4C) and RKO (Fig. 4D) reduced levels of b-catenin pro-
465teins. The effect is also more marked in RKO cells, where the
466siRNA-mediated knockdown of DNMT1 dramatically reduced
467levels of Dnmt1 and b-catenin.
468Regulatory mechanisms of the Dnmt1–b-catenin protein–
469protein interaction
470We next tested two HCT116 derivative cell lines in which
471either the wild-type CTNNB1 allele (CTNNB1/D45-HCT116)
472or mutant CTNNB1 allele (CTNNB1WT/-HCT116) was dis-
473rupted (30). Using two different clones for each cell-line,
474we analyzed expression of b-catenin and Dnmt1. As shown
475in Fig. 5A, the levels of Dnmt1 protein are decreased in
476CTNNB1WT/-HCT116 cells, in line with the decreased levels
477of b-catenin in CTNNB1WT/-HCT116 as compared with
478CTNNB1/D45-HCT116 cells. Nuclear and cytosolic subcellular
479fractionations show a substantial reduction of Dnmt1 protein
480in the nucleus of the cells expressing only wild-type b-catenin
481(Fig. 5B). We next stimulated each of these cell lines with
482exogenous Wnt3A (Fig. 5C and D). The levels of b-catenin
483show a more robust response in the wild-type b-catenin cells as
484compared with the mutant b-catenin cells, and this response is
485reﬂected in the levels of Dnmt1 protein, which show a more
486marked increase in response to Wnt3A in the wild-type b-cate-
487nin cells than in the mutant b-catenin cells. We also tested
488whether the Dnmt1 response was responsive to exogenous
489Wnt stimulation in CTNNB1KO-HCT116 cells. HCT116 and
490CTNNB1KO-HCT116 cells were treated with Wnt3a and West-
491ern analysis performed (Supplementary Fig. S4). As expected,
492Wnt3a only stabilizes Dnmt1 in the HCT116 cells, showing
493that the stabilization of Dnmt1 in response to Wnt3A requires
494b-catenin. Indeed, in these experiments, we observed a slight
495decrease of Dnmt1 abundance in CTNNB1KO-HCT116 cells
496treated with Wnt3A when compared with CTNNB1KO-HCT116
497cells not treated with Wnt3A, suggesting that a b-catenin–
498independent Wnt-mediated mechanism may also regulate
499Dnmt1 expression.
500Because Dnmt1 protein plays a central role in DNA methyla-
501tion during cell division and DNA replication (32, 33), we also
502tested whether Wnt-driven modulation of Dnmt1 protein levels
503might be attributed to cell-cycle regulation following Wnt3a
504stimulation. Flow cytometry was performed on cells harvested
Figure 2.
Nuclear colocalization of Dnmt1 and b-catenin proteins. A, Dnmt1 protein
colocalizeswith b-catenin protein in HCT116 cells. B, Dnmt1 protein colocalizes
with b-catenin protein in Wnt3a stimulated HCT116 cells. Images shown were
captured by confocal microscopy. Dnmt1 is shown in red (anti–mouse-
AlexaFluor594 secondary antibody); b-catenin is shown in green (anti–
rabbit-AlexaFluor488 secondary antibody) and colocalization of Dnmt1 and
b-catenin yellow (overlay images iv show all three colors). DAPI was used for
cell nuclear staining (Blue); scale bar, 10 mm.
(Continued.) (M, standard protein marker; r, biologic replicate; Nuc, nuclear fractions; Cyto, cytoplasmic fractions; IP, immunoprecipitation; IB,
immunoblotting; Input indicates equal loading for IP experiments). G, the central portion of Dnmt1 interacts with b-catenin. HEK293 cells were transfected with
plasmids expressing full-length Myc-tagged Dnmt1 (F), three Myc-tagged Dnmt1 deletion constructs (A–C) as shown in the diagram of Dnmt1 protein
as well as empty plasmid vector (Vec.). Cell lysates were immunoprecipitated with anti-Myc antibodies and cell lysate from nontransfected HEK293
cells (Con.) were used as immunoprecipitation control. Elution fractions were then loaded on SDSPAGE followed by Western blot analyses with
anti–b-catenin antibodies. M refers to standard protein marker.Q5
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Figure 3.
The Dnmt1–b-catenin association is mutually stabilizing. A, knockout of CTNNB1 leads to reduced abundance of endogenous Dnmt1. Twenty
micrograms of total protein lysate from CTNNB1KO-HCT116 or HCT116 cells was loaded on SDSPAGE followed by Western blot analyses with anti-Dnmt1,
anti–b-catenin, anti–g-catenin, anti-HAUSP, and anti-GAPDH. One step RT-PCR was performed on the total RNA extracted from both HCT116 and
CTNNB1KO-HCT116 cells with speciﬁc primer pairs for Dnmt1 and GAPDH (as loading control). B, knockout of DNMT1 leads to reduced abundance of
endogenous b-catenin. Twenty micrograms of total protein lysate from DNMT1KO-HCT116or HCT116 cells was loaded on SDSPAGE followed by Western
blot analyses with anti-Dnmt1, anti–b-catenin, and anti-GAPDH. One step RT-PCR was performed on the total RNA extracted from both HCT116 and
DNMT1KO-HCT116 cells with speciﬁc primer pairs for CTNNB1 and GAPDH (as loading control). M refers to standard protein marker. C, Dnmt1 protein
expression is rescued in CTNNB1KO-HCT116 cells by addition of b-catenin. b-Catenin protein expression level was restored by making transient transfection
in CTNNB1KO-HCT116 cells with plasmid vector containing full-length b-catenin. Total protein lysate (20 mg) from HCT116, CTNNB1KO-HCT116, or
CTNNB1KO-HCT116 with ectopic expressed b-catenin cells was loaded on SDSPAGE followed by Western blot analyses with anti-Dnmt1, anti–b-catenin,
anti–b-catenin (active), and anti-GAPDH (loading control). M refers to standard protein marker. D, b-catenin expression is not rescued in DNMT1KO-HCT116
cells by addition of Dnmt1 protein. (Continued on the following page.)
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507 across the 24 hours time course following Wnt3a treatment. No
508 gross alterations of relative numbers of cells at each time point
509 were apparent (Supplementary Fig. S1), and we therefore con-
510 cluded that the response of Dnmt1 protein levels to Wnt3a
511 treatment is not cell-cycle related.
512 To investigate mechanisms by which b-catenin regulates Dnmt1
513 protein levels, we analyzed the expression of several Dnmt1 inter-
514 acting proteins, including proteins that regulate Dnmt1 stability
515 through methylation (SET7, LSD1; refs. 16, 34). Immunoblots of
516 these proteins were performed on lysates from HCT116 and
517 CTNNB1KO-HCT116 cells as shown in Fig. 6A and B. We were
518 particularly interested by the reduction in levels of LSD1 protein in
519 CTNNB1KO-HCT116 cells. LSD1 (KDM1A) encodes a lysine-spe-
520 ciﬁc demethylase, which has been shown to stabilize Dnmt1
521 through demethylation (35). As a negative control, we also immu-
522 noblotted a related lysine-speciﬁc demethylase, KDM3B, and
523 found no difference in the levels of KDM3B protein between
524 HCT116 and CTNNB1KO-HCT116 cells (Fig. 6A). It may be that
525 the reduction in LSD1 protein levels is attributable to destabiliza-
526 tionofDnmt1–LSD1proteincomplexesby the reductionofDnmt1
528in and CTNNB1KO-HCT116 cells. We next tested whether LSD1
529protein was present in anti–b-catenin immunoprecipitates. Co-IP
530using anti–b-catenin showed that both Dnmt1 and LSD1 proteins
531were present (Fig. 6B), indicating that LSD1 is present in Dnmt1–
532b-catenin protein complexes, and indicating that LSD1 may func-
533tion in the b-catenin–dependent regulation of Dnmt1.
534Functional consequences of the Dnmt1–b-catenin protein–
535protein interaction
536Our results predict that Wnt/b-catenin signaling should be
537altered according to Dnmt1-dependent regulation of b-catenin
538protein levels. We ﬁrst compared TCF-reporter (TOPFlash) activ-
539ity in cells transfected with DNMT1 expression vector in HCT116
540and CTNNB1/D45-HCT116 (Fig. 7A). Next, we compared b-cate-
541nin/TCF signaling in DNMT1KO-HCT116 and HCT116 cells trea-
542ted with siRNA to reduce Dnmt1 levels as shown in Fig. 7B.
543Overexpression of DNMT1 increases TCF reporter activity
544approximately 2-fold and targeting of DNMT1 via siRNA or
545knockout reduces b-catenin signaling (2- and 4-fold, respec-
546tively; all P < 0.05 Student t test). In RKO cells and
Figure 4.
siRNA analysis of the Dnmt1–b-catenin
association. Knockdown of CTNNB1
leads to reduced abundance of
endogenous Dnmt1 in HCT116 (A) and
RKO (B) cells. HCT116 or RKO cells
were transfected with control siRNA
or three independent siRNAs against
CTNNB1. Immunoblots were used to
quantify Dnmt1, b-catenin, g-catenin,
and HAUSP with anti-Dnmt1, anti–
b-catenin, anti–g-catenin, anti-HAUSP
sera. GAPDH was used as loading
control. Knockdown of Dnmt1 leads to
reduced abundance of endogenous
CTNNB1 in HCT116 (C) and RKO (D)
cells. HCT116 or RKO cells were
transfected with control siRNA or
three independent siRNAs against
Dnmt1. Immunoblots were used to
quantify Dnmt1and b-catenin with
antibodies against Dnmt1 and
b-catenin, respectively. GAPDH was
used as loading control. M refers to
standard protein marker.
(Continued.) Transient transfection of DNMT1KO-HCT116 cells with plasmid vector containing full-length Dnmt1 does not restore b-catenin expression.
Total protein lysate (20 mg) from HCT116, DNMT1KO-HCT116, or DNMT1KO-HCT116 with ectopically expressed Dnmt1 was loaded on SDSPAGE followed
by Western blot analyses with anti-Dnmt1, anti–b-catenin, and anti-GAPDH (loading control). M refers to standard protein marker. E, degradation proﬁles for
b-catenin and Dnmt1 in HCT116, DNMT1KO-HCT116, or CTNNB1KO-HCT116 cells following cycloheximide treatment. Degradation rate constants were
quantiﬁed by measuring the relative intensity of each protein by quantitative Western blotting at 0, 3, and 6 hours after cycloheximide treatment. The
intensity data were ﬁt to a ﬁrst-order decay function to estimate the degradation rate constant, which then was used to calculate the half-life.
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549 CTNNB1/WT-HCT116 cells, overall levels of TCF reporter activity
550 are much lower (10-fold), as expected (lower b-catenin levels)
551 and statistically signiﬁcant changes in TCF reporter were not
552 detected in either overexpression or RNAi experiments (supple-
553 mentary Information). Although we cannot rule out that knock-
554 down or knock-out of DNMT1 affects TCF signaling through a
555 b-catenin–independent mechanism, these results suggest that
556 Dnmt1 protein regulates Wnt/TCF signaling by stabilizing b-cate-
557 nin in the nucleus.
558 Finally, because DNMT1 is the primary mammalian mainte-
559 nance DNA methyltransferase, we sought to determine whether
561destabilization of Dnmt1 in the absence of b-catenin also alters
562CpG methylation patterns. The H19 imprinted locus encodes a
563non–protein-coding RNA and functions as a tumor suppressor
564(35). We also previously found that the H19 imprinted locus
565was a sensitive marker for DNMT1 methylation activity in
566HCT116 cells (15). We therefore compared the CpGmethylation
567status of approximately 20 clones each of HCT116 and
568CTNNB1KO-HCT116 cells. As shown in Fig. 7C, there is signiﬁ-
569cantly reduced methylation in the CTNNB1KO-HCT116 cells at
570several CpG loci, indicating that the lower levels of Dnmt1 pro-
571tein in CTNNB1KO-HCT116 cells has a knockon effect on DNA
Figure 5.
Immunoblot analysis of Dnmt1 expression in cells expressing mutant or wild-type b-catenin. A, immunoblot analysis of cells expressing wild-type b-catenin
(CTNNB1WT/-HCT116) and mutant b-catenin (CTNNB1/D45-HCT116). Total soluble proteins were extracted and compared in two separate clones for
each cell-line, 20 mg of total protein was loaded on SDSPAGE and Western blots were performed using a–b-catenin, a-Dnmt1, and a–a-tubulin (loading
control). B, immunoblot analysis of subcellular fractions of cells expressing wild-type b-catenin (CTNNB1WT/-HCT116) and mutant b-catenin (CTNNB1/D45-
HCT116; two clones for each cell type). For each fraction, a total protein of 20 mg was loaded on SDSPAGE and Western blots were performed using
a–b-catenin and a-Dnmt1. C, Wnt3A time course stimulation of CTNNB1WT/-HCT116 (clone D075) and CTNNB1/D45-HCT116 cells (clone K058). Cells were
collected at 0, 1, 3, 6, and 24 hours post Wnt3A (30 ng/mL) stimulation on each cell line followed by total protein extraction. Total protein of 20 mg
was loaded on SDSPAGE and Western blots were performed using a–b-catenin and a-Dnmt1.
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574 methylation activity. In concordance with this ﬁnding, we also
575 observed increased levels ofH19mRNA transcripts in CTNNB1KO
576 -HCT116 as compared with HCT116 cells (Supplementary
577 Fig. S7).
578 Discussion
579 Here, we analyze an interaction between Dnmt1 and b-catenin
580 proteins that mutually regulates the levels of each protein in
581 colorectal cancer cells. The regulation is not mediated via tran-
582 scriptional activation of DNMT1, but instead through the inter-
583 action of Dnmt1 protein with b-catenin in the nucleus. Given the
584 critical roles of both b-catenin and Dnmt1 cells in normal as well
585 as cancer cells, our results point to an important mechanism by
587which the two proteins cross-regulate. We found that the lysine
588demethylase, LSD1, which regulates Dnmt1 stability, is present in
589Dnmt1–b-catenin protein complexes, suggesting that the stabili-
590zation ofDnmt1 in these protein complexes ismediated via lysine
591methylation. We investigated the downstream functional conse-
592quences of the b-catenin–Dnmt1 association, and showed that
593Dnmt1 protein levels regulate b-catenin/TCF signaling and that
594the absence of b-catenin impacts CpG methylation status, point-
595ing to a regulatory link between Wnt/b-catenin signaling and the
596downstream functions of Dnmt1.
597Although protein stability of Dnmt1 and b-catenin is an
598important outcome of the interaction between the proteins, the
599precise molecular mechanisms that result in increased b-catenin/
600TCF signaling activity remain to be determined. Although b-cate-
601nin expression rescues Dnmt1 expression in CTNNB1KO-HCT116
602cells, we did not observe rescue of b-catenin protein levels in
603DNMT1KO-HCT116 cells following expression of Dnmt1 (Fig. 3).
604Thismay imply that the increased b-catenin/TCF signaling activity
605induced by Dnmt1 is not due to stabilization and increased levels
606of b-catenin, but froman alternativemechanismbywhichDnmt1
607increases b-catenin transcriptional activity. Other studies have
608shown that Dnmt1 can regulate transcription through protein
609interactions, in a methylation-independent manner. The Dnmt1
610N-terminus was shown tomediate the interaction of Dnmt1 with
611HDAC and DMAP1 proteins, to form transcriptional repressor
612complexes (11), and many interactions between Dnmt1 and
613transcription factors have been identiﬁed (13). E-cadherin expres-
614sion (in HCT116 cells) is regulated by an interaction between
615Dnmt1 and the transcriptional repressor Snail1, and in the same
616study that loss of the Dnmt1 N-terminal domains promoted
617b-catenin translocation to the nucleus (36). Stabilization of
618Dnmt1 protein, but not alterations of DNMT1 transcript levels
619are the cause of DNMT1 dysregulation in human mammary
620epithelial cells, and this stabilization is mediated via the Dnmt1
621protein N-terminus (37). How LSD1 functions in the Dnmt1–
622b-catenin interaction remains to be determined, because LSD1 is
623known to regulate Dnmt1 stability via demethylation (34). Other
624modifying proteinsmay also be important; interactions ofDnmt1
625protein with HAUSP/USP7, UHRF1 and Tip60 proteins regulate
626Dnmt1 by ubiquitination and acetylation (15, 38). Tip60 inter-
627acts with both Dnmt1 and b-catenin (39), and further mass
628spectrometry analysis will determine whether Tip60 is present in
629b-catenin–Dnmt1 protein complexes. Although we previously
630showed that Tip60 acetylates Dnmt1 protein, which promotes
631Dnmt1 degradation (15), the signiﬁcance of the b-catenin–Tip60
632interaction is as yet undetermined.
633Our study points to a mechanism of cross-talk between Wnt
634signaling and DNA methylation mediated via a protein–protein
635interaction between b-catenin and Dnmt1. How this cross-talk
636manifests itself in tumors is as yet unknown, although in mouse,
637hypomorphic Dnmt1 alleles in the ApcMin background substan-
638tially reduce the number of polyps observed (40). Although the
639suppression of polyp formation was attributed to decreased CpG
640island methylation in the Dnmt1 hypomorphic mice, reduced
641Dnmt1 protein levels may also suppress polyp formation by
642destabilizing b-catenin and reducing Wnt/b-catenin–driven tran-
643scriptional activity via the mechanism that we have described.
644Transcriptional regulation of DNMT1 by Wnt has also been
645shown (41). Using colorectal HT-29 cells (expressing truncated
646APC) the authors showed that transfection of full-length APC
647reduces DNMT1 mRNA and DNMT1 promoter–reporter activity.
Figure 6
Analysis of known Dnmt1 interacting and regulatory proteins. A, anti–
b-catenin immunoprecipitates both Dnmt1 and LSD1 proteins in HCT116
cells. Total protein lysate from HCT116 or immunoprecipitates was blotted
with b-catenin, Dnmt1, and LSD1 antibodies. B, immunoblot analysis of
HCT116 and CTNNB1 knockout (CTNNB1KO-HCT116) cells (two replicates
each) of Dnmt1 interacting and regulatory proteins. Total soluble proteins
were extracted and compared in two separate clones for each cell-line
(Clones are indicated as 1 and 2), 20 mg of total protein was loaded on
SDSPAGE and Western blots were performed using anti-SET7, anti-LSD1
(lysine demethylase regulating Dnmt1 stability) antibody, and related
lysine demethylase anti-KDM3B.
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650 In addition, the authors also inhibited TCF-driven transcription
651 using a dominant-negative TCF and found that this also reduces
652 DNMT1 mRNA levels, indicating transcriptional control of
653 DNMT1 expression. In our study, we do not observe transcrip-
654 tional effects of Wnt/b-catenin on DNMT1 (as measured by
655 steady-state RNA levels), but instead observed dramatic effects
656 of Wnt and b-catenin on Dnmt1 protein levels. These differences
657 may imply that activation of Wnt/b-catenin by APC mutations is
658 not entirely functionally equivalent to activation by stabilizing
659 CTNNB1/b-catenin mutations. We also note, as did the authors
660 of the previous study, that there are no apparent TCF-binding
661 sites in the DNMT1 promoter, and so the transcriptional activa-
662 tion of DNMT1 is unlikely to be mediated via direct binding of
663 b-catenin/TCF in theDNMT1promoter. Taken together, our study
664 and these previous studies show that multilayered communica-
665 tion exists between DNMT1 and Wnt/b-catenin signaling.
666 Although these and previous studies have been performed in
667 cancer cell models, future work should establish the possible
669importance of cross-talk between DNMT1 and Wnt/b-catenin
670signaling in clinical samples. In addition, although our study has
671identiﬁed that an interaction between Wnt/b-catenin and Dnmt1
672may alter DNA methylation patterns on a speciﬁc locus, it would
673be interesting to measure global patterns of DNA methylation
674to see how widespread this effect is.
675Interestingly, several studies have demonstrated methylation-
676independent functions for Dnmt1. In HCT116 cells, Dnmt1
677proteins lacking the C-terminal catalytic domain function as
678transcriptional repressors at speciﬁc loci (12). The authors spec-
679ulated that Dnmt1 serves as a scaffold for recruitment of tran-
680scriptional repressive complexes, including interaction with the
681LSD1 histone demethylase. Intriguingly, knockdown of Dnmt1
682protein was shown to regulate gene expression via a methylation-
683independent and histone deacetylation–independent mecha-
684nism (42). Our analysis showed that knockdown of Dnmt1
685protein can regulate TCF/b-catenin transcriptional activity. Future
686studies will establish whether Dnmt1 protein levels also regulate
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Figure 7.
Functional consequences of the Dnmt1–b-catenin interaction. A, TCF (luciferase) reporter activity in HCT116 and CTNNB1/D45-HCT116 (mutant b-catenin)
cells (B) TCF (luciferase) reporter activity in HCT116 and RKO cells (treated with DNMT1 siRNAs) as well as DNMT1KO-HCT116 and CTNNB1KO-HCT116 cells.
All cells were transfected with LEF/TCF reporter. Negative and positive controls were also used for signal normalization and transfection efﬁciency
monitoring. Dual Luciferase assay was performed 48 hours after transfection and promoter activity values were expressed as arbitrary units using a Renilla
reporter for internal normalization. Experiments were done in triplicates for biologic cell cultures/transfections and luminescent measurements.
Average numbers (bar height) of relative luciferase units for each sample plus standard deviation (error bar) were plotted relative to maximum. C,
methylated CpG sites are decreased in CTNNB1 KO cells at the H19 locus, especially on the ﬁrst six (1, 3, 4, 5, 6, and 7) of seven CpG sites. Genomic DNAs
from wild-type HCT116 (WT) and CTNNB1 knockout HCT116 (KO) clones were bisulﬁte treated. The CpG island of H19 locus was PCR ampliﬁed, cloned,
and sequenced with the Sanger sequencing method. Twenty one and 19 clones were sequenced for WT and KO, respectively (methylated CpG sites are black
spots, nonmethylated CpG sites are white spots and DNA sequences are represented as black lines).
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689 endogenous Wnt/b-catenin targets. The role played by chromatin
690 should also be considered. The interplay between soluble nuclear
691 Dnmt1 proteins and chromatin-associated Dnmt1 is complex.
692 For example, Dnmt1 protein forms soluble complexes with
693 USP7 that then form trimeric complexes with chromatin-bound
694 UHRF1 (28). In addition, in contrast with DNMT3A/B, a sub-
695 stantial portion of Dnmt1 protein appears to exist as a soluble
696 pool in the nucleus rather than being associated with chromatin
697 (43, 44). Finally, although the primary nuclear function of
698 b-catenin is to regulate transcription via association with TCF
699 transcription factors, our study shows that regulation of other
700 proteins via stabilizing protein–protein interactions may also be
701 an important function of nuclear b-catenin.
702 In summary, our work identiﬁes a novel mechanism by which
703 the levels of two key oncoproteins, b-catenin and Dnmt1 are
704 regulated in cancer cells. The b-catenin–Dnmt1 interaction sta-
705 bilizes each protein, and in turn regulates downstream b-catenin
706 and Dnmt1 functions. Our study indicates a possible cancer-
707 relevant mechanism of cross-regulation between Wnt signaling
708 andDNAmethylation. Given that theWnt pathway plays a critical
709 role in development and tissue differentiation, the mechanism
710 revealed in this study could also explain howWnt signaling drives
711 tissue differentiation.
712 Disclosure of Potential Conﬂicts of Interest
713 No potential conﬂicts of interest were disclosed.Q6
715Authors' Contributions
716Conception and design: J. Song, B. Dong, Z. Wang, R.M. Ewing
717Development of methodology: J. Song, Z. Du, B. Dong, R.M. Ewing
718Acquisition of data (provided animals, acquired and managed patients,
719provided facilities, etc.): J. Song, Z. Du, M. Ravasz, B. Dong, Z. Wang
720Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
721computational analysis): J. Song, M. Ravasz, B. Dong, Z. Wang, R.M. Ewing
722Writing, review, and/or revision of themanuscript: J. Song, B. Dong, Z. Wang,
723R.M. Ewing
724Administrative, technical, or material support (i.e., reporting or organizing
725data, constructing databases): J. Song, M. Ravasz, B. Dong, R.M. Ewing
726Study supervision: J. Song, B. Dong, R.M. Ewing Q7
727Grant Support
728R.M. Ewing and Z. Wang acknowledge NCI award 1R21CA16006 that
729supported in part the work described here. R.M. Ewing was supported by an
730EUMarie Curie FP7-PEOPLE-2012-CIG award. Z. Wang was supported by NCI
731award P50CA150964. J. Song was supported by the Cancer Pharmacology
732Training Program (R25CA148052) at Case Western Reserve University. J. Song
733acknowledges support via NIH S10RR017980 for use of the Imaging Facility,
734Department of Genetics and Genome Sciences.
735The costs of publication of this article were defrayed in part by the
736payment of page charges. This article must therefore be hereby marked
737advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate
738this fact.
739Received December 12, 2013; revised January 14, 2015; accepted January 26,
7402015; published OnlineFirst xx xx, xxxx.
741 References
742 1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell
743 2011;144:646–74.
744 2. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al.
745 Activation of beta-catenin-Tcf signaling in colon cancer by mutations in
746 beta-catenin or APC. Science 1997;275:1787–90.
747 3. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell
748 1996;87:159–70.
749 4. Yakulov T, Raggioli A, Franz H, Kemler R. Wnt3a-dependent and
750 -independent protein interaction networks of chromatin-bound b-cate-
751 nin in mouse embryonic stem cells. Mol Cell Proteomics MCP 2013;12:
752 1980–94.Q8
753 5. Mosimann C, Hausmann G, Basler K. Beta-catenin hits chromatin:
754 regulation of Wnt target gene activation. Nat Rev Mol Cell Biol 2009;
755 10:276–86.
756 6. Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and
757 cancer. Adv Exp Med Biol 2013;754:3–29.
758 7. Saito Y, Kanai Y, Nakagawa T, SakamotoM, SaitoH, Ishii H, et al. Increased
759 protein expression of DNA methyltransferase (DNMT) 1 is signiﬁcantly
760 correlated with the malignant potential and poor prognosis of human
761 hepatocellular carcinomas. Int J Cancer J Int Cancer 2003;105:527–32.
762 8. Girault I, Tozlu S, Lidereau R, Bieche I. Expression analysis of DNA
763 methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin
764 Cancer Res 2003;9:4415–22.
765 9. Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, et al.
766 Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal
767 hematopoiesis and in acute and chronic myelogenous leukemia. Blood
768 2001;97:1172–9.
769 10. De Marzo AM, Marchi VL, Yang ES, Veeraswamy R, Lin X, Nelson WG.
770 Abnormal regulation of DNA methyltransferase expression during colo-
771 rectal carcinogenesis. Cancer Res 1999;59:3855–60.
772 11. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new
773 co-repressor, DMAP1, to form a complex at replication foci. Nat Genet
774 2000;25:269–77.
775 12. Clements EG, Mohammad HP, Leadem BR, Easwaran H, Cai Y, Van Neste
776 L, et al. DNMT1 modulates gene expression without its catalytic activity
777 partially through its interactions with histone-modifying enzymes.Nucleic
778 Acids Res 2012;40:4334–46.
78013. QinW, Leonhardt H, Pichler G. Regulation of DNAmethyltransferase 1 by
781interactions and modiﬁcations. Nucl Austin Tex 2011;2:392–402.
78214. Kinney SRM, Pradhan S. Regulation of expression and activity of DNA
783(cytosine-5) methyltransferases in mammalian cells. Prog Mol Biol Transl
784Sci 2011;101:311–33.
78515. Du Z, Song J, Wang Y, Zhao Y, Guda K, Yang S, et al. DNMT1 stability is
786regulated by proteins coordinating deubiquitination and acetylation-driv-
787en ubiquitination. Sci Signal 2010;3:ra80.
78816. Esteve P-O, Chin HG, Benner J, Feehery GR, Samaranayake M, Horwitz
789GA, et al. Regulation of DNMT1 stability through SET7-mediated lysine
790methylation in mammalian cells. Proc Natl Acad Sci U S A 2009;106:
7915076–81.
79217. Song J, Wang Z, Ewing RM. Integrated analysis of the Wnt responsive
793proteome in human cells reveals diverse and cell-type speciﬁc networks.
794Mol Biosyst 2014;10:45–53. Q9
79518. Gassmann M, Grenacher B, Rohde B, Vogel J. Quantifying Western blots:
796pitfalls of densitometry. Electrophoresis 2009;30:1845–55.
79719. Tan HY, Ng TW. Accurate step wedge calibration for densitometry of
798electrophoresis gels. Opt Commun 2008;281:3013–7.
79920. Jimenez CR, Huang L, Qiu Y, Burlingame AL. In-gel digestion of proteins
800for MALDI-MS ﬁngerprint mapping. Curr Protoc Protein Sci 2001;Chapter
80116:Unit 16.4.
80221. Searle BC. Scaffold: a bioinformatic tool for validating MS/MS-based
803proteomic studies. Proteomics 2010;10:1265–9.
80422. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for
805identifying proteins by tandem mass spectrometry. Anal Chem 2003;75:
8064646–58.
80723. VeemanMT, SlusarskiDC, Kaykas A, Louie SH,MoonRT. Zebraﬁsh prickle,
808a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation
809movements. Curr Biol 2003;13:680–5.
81024. Belle A, Tanay A, Bitincka L, Shamir R,O'Shea EK.Quantiﬁcation of protein
811half-lives in the budding yeast proteome. Proc Natl Acad Sci U S A 2006;
812103:13004–9.
81325. Song J, Hao Y, Du Z, Wang Z, Ewing RM. Identifying novel protein
814complexes in cancer cells using epitope-tagging of endogenous human
815genes and afﬁnity-puriﬁcation mass spectrometry. J Proteome Res 2012;
81611:5630–41.
Song et al.
Mol Cancer Res; 2015 Molecular Cancer Research12
819 26. Ewing RM, Chu P, Li H, Taylor P, Climie S, McBroom L, et al. Large-scale
820 mapping of human protein–protein interactions by mass spectrometry.
821 Mol Syst Biol 2007;3:89.
822 27. Dazard J-EJ, Saha S, Ewing RM. ROCS: a reproducibility index and conﬁ-
823 dence score for interaction proteomics. BMC Bioinformatics 2012;13:128.
824 28. Felle M, Joppien S, Nemeth A, Diermeier S, Thalhammer V, Dobner T, et al.
825 The USP7/Dnmt1 complex stimulates the DNA methylation activity of
826 Dnmt1 and regulates the stability of UHRF1. Nucleic Acids Res 2011;39:
827 8355–65.
828 29. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW, et al. CpG
829 methylation is maintained in human cancer cells lacking DNMT1. Nature
830 2000;404:1003–7.
831 30. Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW. Targeted inactiva-
832 tion of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc
833 Natl Acad Sci U S A 2002;99:8265–70.
834 31. Maeda O, Usami N, Kondo M, Takahashi M, Goto H, Shimokata K, et al.
835 Plakoglobin (gamma-catenin) has TCF/LEF family-dependent tran-
836 scriptional activity in beta-catenin-deﬁcient cell line. Oncogene 2004;
837 23:964–72.
838 32. Unterberger A, Andrews SD,Weaver ICG, SzyfM.DNAmethyltransferase 1
839 knockdown activates a replication stress checkpoint. Mol Cell Biol 2006;
840 26:7575–86.
841 33. Easwaran HP, Schermelleh L, Leonhardt H, Cardoso MC. Replication-
842 independent chromatin loadingofDnmt1duringG2andMphases. EMBO
843 Rep 2004;5:1181–6.
844 34. Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J, et al. The lysine
845 demethylase LSD1 (KDM1) is required for maintenance of global DNA
846 methylation. Nat Genet 2009;41:125–9.
847 35. Yoshimizu T, Miroglio A, Ripoche M-A, Gabory A, Vernucci M, Riccio A,
848 et al. TheH19 locus acts in vivo as a tumor suppressor. ProcNatl Acad SciUS
849 A 2008;105:12417–22.
85136. Espada J, Peinado H, Lopez-Serra L, Setien F, Lopez-Serra P, Portela A,
852et al. Regulation of SNAIL1 and E-cadherin function by DNMT1 in a
853DNA methylation-independent context. Nucleic Acids Res 2011;39:
8549194–205.
85537. Agoston AT, Argani P, Yegnasubramanian S, Marzo AM De, Ansari-Lari
856MA, Hicks JL, et al. Increased protein stability causes DNA methyl-
857transferase 1 dysregulation in breast cancer. J Biol Chem 2005;280:
85818302–10.
85938. QinW, Leonhardt H, Spada F. Usp7 andUhrf1 control ubiquitination and
860stability of the maintenance DNA methyltransferase Dnmt1. J Cell Bio-
861chem 2011;112:439–44.
86239. Sierra J, Yoshida T, Joazeiro CA, Jones KA. The APC tumor suppressor
863counteracts beta-catenin activation and H3K4 methylation at Wnt target
864genes. Genes Dev 2006;20:586–600.
86540. Eads CA, Nickel AE, Laird PW. Complete genetic suppression
866of polyp formation and reduction of CpG-island hypermethyla-
867tion in ApcMin/þDnmt1-hypomorphic mice. Cancer Res 2002;62:
8681296–9.
86941. Campbell PM, Szyf M. Human DNA methyltransferase gene DNMT1 is
870regulated by the APC pathway. Carcinogenesis 2003;24:17–24.
87142. Milutinovic S, Brown SE, Zhuang Q, Szyf M. DNA methyltransferase 1
872knock down induces gene expression by a mechanism independent of
873DNA methylation and histone deacetylation. J Biol Chem 2004;279:
87427915–27.
87543. Jeong S, Liang G, Sharma S, Lin JC, Choi SH, Han H, et al. Selec-
876tive anchoring of DNA methyltransferases 3A and 3B to nucleo-
877somes containing methylated DNA. Mol Cell Biol 2009;29:
8785366–76.
87944. Rothbart SB, Krajewski K, Nady N, Tempel W, Xue S, Badeaux AI, et al.
880Association of UHRF1 with methylated H3K9 directs the maintenance of
881DNA methylation. Nat Struct Mol Biol 2012;19:1155–60.
www.aacrjournals.org Mol Cancer Res; 2015 13
Functional Protein Interaction between Dnmt1 and b-Catenin
AUTHOR QUERIES
AUTHOR PLEASE ANSWER ALL QUERIES
Q1: Page: 1: Author: Per journal style, genes, alleles, loci, and oncogenes are italicized;
proteins are roman. Please check throughout to see that the words are styled correctly.
AACR journals have developed explicit instructions about reporting results from experi-
ments involving the use of animalmodels as well as the use of approved gene and protein
nomenclature at their ﬁrst mention in the manuscript. Please review the instructions at
http://www.aacrjournals.org/site/InstrAuthors/ifora.xhtml#genenomen to ensure that
your article is in compliance. If your article is not in compliance, please make the
appropriate changes in your proof.
Q2: Page: 1: Author: Please verify the drug names and their dosages used in the article.
Q3: Page: 1: Author: Please verify the fax details of the corresponding author "RobM. Ewing"
for correctness.
Q4: Page: 2: Author: Please verify the abbreviated form of "coimmunoprecipitation" for
correctness.
Q5: Page: 6: Author: Please conﬁrmquality/labeling of all images includedwithin this article.
Thank you.
Q6: Page: 12: Author/PE: The conﬂict-of-interest disclosure statement that appears in the
proof incorporates the information from forms completed and signed off on by each
individual author. No factual changes can bemade to disclosure information at the proof
stage. However, typographical errors or misspelling of author names should be noted on
theproof andwill be corrected before publication. Please note if any such errors need tobe
corrected. Is the disclosure statement correct?
Q7: Page: 12: Author: The contribution(s) of each author are listed in the proof under the
heading "Authors' Contributions." These contributions are derived from forms complet-
ed and signed off on by each individual author. As the corresponding author, you are
permitted to make changes to your own contributions. However, because all authors
submit their contributions individually, you are not permitted to make changes in the
contributions listed for any other authors. If you feel strongly that an error is beingmade,
then you may ask the author or authors in question to contact us about making the
changes. Please note, however, that themanuscript would be held from further processing
until this issue is resolved. Author: Please mention authors' contributions for the author
"B. Dong."
Q8: Page: 12: Author: Ref. has been updated with PubMed. Please verify.
Q9: Page: 12: Author: Ref. 17 has been updated with PubMed. Please verify.
AU: Below is a summary of the name segmentation for the authors according to our records.
The First Name and the Surname data will be provided to PubMed when the article is indexed
for searching. Please check each name carefully and verify that theFirstName andSurname are
correct. If a name is not segmented correctly, please write the correct First Name and Surname
on this page and return it with your proofs. If no changes are made to this list, we will assume
that the names are segmented correctly, and the names will be indexed as is by PubMed and
other indexing services.
First Name Surname
Jing Song
Zhanwen Du
Mate Ravasz
Bohan Dong
Zhenghe Wang
Rob M. Ewing
